Objective To investigate and analyze the incidence of hepatitis B virus (HBV) infection and related cirrhosis in a certain area. Methods A retrospective investigation was performed on 365 patients with HBV infection in a certain area from October 2018 to October 2020. The relevant data of the patients and the incidence of HBV infection-related cirrhosis were analyzed to explore the influencing factors for liver cirrhosis caused by HBV infection. Results The age of patients with HBV infection was mainly 31-50 years old (61.92%), who were mainly males (80.00%). The symptoms included yellow urine (66.30%), loss of appetitte (57.53%) and fatigue (46.85%). There was abnormal increase of aspartate aminotransferase and alanine aminotransferase, and hyperbilirubinemia in patients. 35 patients developed liver failure, of whcih 31 patients survived and were discharged, 3 patients underwent liver transplantation and 1 patient died after discharge. Among the 365 patients, there were 82 cases with HBV-related cirrhosis, mainly aged between 31 and 50 years old (63.41%), who were mainly males (80.00%). The main symptoms included abdominal distension (46.34%), liver palm (39.02%) and jaundice (34.15%), and all were accompanied with abnormal liver function indexes. Of the 365 patients, 35.37% of them were complicated with primary peritonitis, and 25.61% with electrolyte imbalance. In addition, 87.80% of the patients improved and were discharged. The incidence rates of upper gastrointestinal bleeding, hepatic encephalopathy and death were 7.32%, 3.66% and 1.22%, respectively. The results of univariate and multivariate analysis showed that drinking history, HBV-DNA level and exercise were the influencing factors of HBV-related cirrhosis (P<0.05). Conclusion Patients with HBV infection and related cirrhosis are mostly middle-aged men. Drinking history, HBV-DNA level and exercise are important influencing factors for HBV infection progression to cirrhosis.

Background and objective Epidermal growth factor receptor (EGFR) is commonly overexpressed in lung squamous cell carcinoma and has been associated with impaired prognosis. hTe aim of this study was to observe the ef-ifcacy and safety of nimotuzumab, a anti-EGFR monoclonal antibody, combined with chemotherapy as second- or later-line in the treatment of advanced lung squamous cell carcinoma.Methods A retrospective analysis of clinical data was conducted in 13 patients with advanced lung squamous cell carcinoma, who were administered with nimotuzumab combined with chemo-therapy as second-line or later-line treatment. hTe effcacy of therapy was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and safety by National Cancer Institute Common Toxicity Criteria (NCI-CTC) 4.0.Results Of the 13 advanced squamous-cell lung cancer patients, one patient had complete response (CR), 2 patients had partial re-sponse (PR), 4 cases had stable disease (SD), and 6 patients had progressive disease. hTe overall response rate (ORR) was 23.1% and clinical beneift rate (CBR) was 53.8%. EGFR expression were detected by immunohistochemistry in 6 patients and the results showed 5 patients were EGFR 3+ and the other was EGFR 2+. Of these 6 EGFR positive patients, 1 case had CR, 1 case had PR and 4 cases had SD; ORR was 33.3% and CBR was 100.0%. Grade 3/4 hematological toxicities were observed in 3 (23.1%) patients, and non-hametological toxicities were mild. Nimotuzumab-associated skin rash was found in 2 (15.4%) patients.ConclusionNimotuzumab combined with chemotherapy as second- or later-line therapy for advanced squamous cell lung carcinoma was active and well-tolerated, especially for those patients with EGFR positive.